Organizational Chart International Technology Transfer General Information Career Opportunities


Spacer

 
Licensing & Royalties
spacer
 

Licensing Opportunities

Technology Abstracts

Print This Abstract Apply Questions ?
Eosinophil-Derived Neurotoxin, an Antimicrobial Protein with Ribonuclease Activity, is an Immunostimulant

Description of Invention:
Eosinophil-derived neurotoxin (EDN) has in vitro anti-viral activity that is dependent on its ribonuclease activity. This invention discloses that EDN is a selective chemoattractant and activator of dendritic cells, resulting in dendritic cell migration, maturation, and the production of a wide variety of cytokines. Based on these potent chemotactic and activating effects on dendritic cells, EDN might be useful as a clinical immunoadjuvant for the promotion of immune responses to specific antigens of tumors or pathogenic organisms.

Inventors:
De Yang et al. (NCI)

Patent Status:
DHHS Reference No. E-191-2003/1 --
U.S. Patent Application No. 10/834,733 filed 29 Apr 2004

Portfolios:
Infectious Diseases
Cancer

Cancer -Therapeutics-Immunomodulators and Immunostimulants
Infectious Diseases -Therapeutics-Anti-Viral
Cancer -Therapeutics
Infectious Diseases -Therapeutics

For Additional Information Please Contact:
David A. Lambertson Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-4632
Email: lambertsond@mail.nih.gov
Fax: (301) 402-0220


Web Ref: 819

Updated: 1/05

 

 
 
Spacer